logo

FDA Calendar

Share
Company Name Pfizer Inc.
Drug Name XELJANZ 5 mg and 10 mg (sNDA)
Event Name FDA panel to review XELJANZ proposed for the treatment of adult patients with moderately to severely active ulcerative colitis
Event Date 03/08/2018
Outcome Date 03/08/2018
Outcome FDA panel recommended
Drug Status
Rival Drugs
Market Potential
Other Approvals XELJANZ already approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis and adult patients with active psoriatic arthritis.
News
Return to FDA Calendar